- Home
- HIFS vs DNTH Comparison
HIFS vs DNTH Comparison
Compare HIFS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIFS
- DNTH
- Stock Information
- Founded
- HIFS 1834
- DNTH 2015
- Country
- HIFS United States
- DNTH United States
- Employees
- HIFS N/A
- DNTH N/A
- Industry
- HIFS Major Banks
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- HIFS Finance
- DNTH Health Care
- Exchange
- HIFS Nasdaq
- DNTH Nasdaq
- Market Cap
- HIFS 611.4M
- DNTH 606.2M
- IPO Year
- HIFS N/A
- DNTH N/A
- Fundamental
- Price
- HIFS $239.81
- DNTH $20.59
- Analyst Decision
- HIFS
- DNTH Strong Buy
- Analyst Count
- HIFS 0
- DNTH 8
- Target Price
- HIFS N/A
- DNTH $53.00
- AVG Volume (30 Days)
- HIFS 54.4K
- DNTH 363.5K
- Earning Date
- HIFS 07-11-2025
- DNTH 08-11-2025
- Dividend Yield
- HIFS 1.06%
- DNTH N/A
- EPS Growth
- HIFS 63.41
- DNTH N/A
- EPS
- HIFS 15.35
- DNTH N/A
- Revenue
- HIFS $75,066,000.00
- DNTH $6,524,000.00
- Revenue This Year
- HIFS N/A
- DNTH N/A
- Revenue Next Year
- HIFS N/A
- DNTH N/A
- P/E Ratio
- HIFS $15.95
- DNTH N/A
- Revenue Growth
- HIFS 37.00
- DNTH 102.36
- 52 Week Low
- HIFS $209.71
- DNTH $13.37
- 52 Week High
- HIFS $300.00
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- HIFS 39.19
- DNTH 52.74
- Support Level
- HIFS $244.00
- DNTH $21.27
- Resistance Level
- HIFS $250.64
- DNTH $23.21
- Average True Range (ATR)
- HIFS 7.79
- DNTH 1.25
- MACD
- HIFS -2.47
- DNTH -0.07
- Stochastic Oscillator
- HIFS 10.28
- DNTH 39.77
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.